ALPN Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ALPN shares is 243, representing 99.47% of the company's common stock.

VIVO CAPITAL, LLC, in the last quarter, reduced its stake in ALPN by -36.47% restricting it's holding to 520.51 thousand shares of worth nearly $20.79M. FRANKLIN RESOURCES INC also lessened -10.42% of the ALPN shares from its portfolio, reducing its holding to 1.09 million shares of worth $43.33M. WALLEYE CAPITAL LLC also shunned ALPN shares holding by -43.68% last quarter which brought its holding to 206.1 thousand shares worth $8.17M.

As per its latest 13F filing, FIRST LIGHT ASSET MANAGEMENT, LLC increased its stake in ALPN by 100% in the last quarter. The institutional holder raised its holding to 501.24 thousand shares having worth more than $19.87M. NUVEEN ASSET MANAGEMENT, LLC also added 294.85% more shares of ALPN to its portfolio, raising its holding to 513.18 thousand shares of worth $20.34M. TWO SIGMA INVESTMENTS, LP also increased its ALPN shares holding by 37.41% which brought its holding to 519.97 thousand shares worth $20.61M.

The insider with the most stakes in ALPN is Decheng Capital China Life Sciences USD Fund III, L.P. , 10 percent owner at the company. Additionally, ALPN stock is highly held by director Topper James N and Venkatesan Jay among others.

Company executives, directors, and other insiders own 4.65% percent of Alpine Immune Sciences, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which ALPN insiders have sold stock, totaling 0 shares. Insiders that have sold shares include TOPPER JAMES N, RICKEY JAMES PAUL, and THOMPSON PETER A..

There have been 0 transaction(s) during the past 6-months in which Alpine Immune Sciences, Inc. insiders have bought stock, totalling 0 shares

Around 0 Alpine Immune Sciences, Inc. shares are held by insiders, which represents about 4.65% of ALPN stock.

ALPN 10 percent owner, Decheng Capital China Life Sciences USD Fund III, L.P. holds the largest portfolio of the company's shares. ALPN shares owned by Decheng total nearly 4.71 million.

FIRST LIGHT ASSET MANAGEMENT, LLC is the largest institutional owner in ALPN which holds 501.24 thousand shares worth $19.87M or 1% of the total ALPN shares outstanding followed by NUVEEN ASSET MANAGEMENT, LLC with ownership of 513.18 thousand shares representing 1.03% of the ALPN ownership. TWO SIGMA INVESTMENTS, LP is the third largest stakeholder with 519.97 thousand shares or 1.04% of the ownership worth more than $20.61M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ALPN is concerned, it is a stock which is not optionable.

Number of ALPN shares short is 3.89M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 68.60M shares of ALPN are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ALPN has 47.88M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ALPN is 0.96.